Liesbeth Reneman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5225852/publications.pdf

Version: 2024-02-01

123 papers	5,660 citations	70961 41 h-index	95083 68 g-index
132 all docs	132 docs citations	132 times ranked	7436 citing authors

#	Article	IF	Citations
1	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The <scp>ENIGMA</scp> adventure. Human Brain Mapping, 2022, 43, 37-55.	1.9	61
2	Targeting working memory to modify emotional reactivity in adult attention deficit hyperactivity disorder: a functional magnetic resonance imaging study. Brain Imaging and Behavior, 2022, 16, 680-691.	1.1	2
3	Effects of a singleâ€dose methylphenidate challenge on restingâ€state functional connectivity in stimulantâ€treatment naive children and adults with ADHD. Human Brain Mapping, 2022, 43, 4664-4675.	1.9	11
4	Measuring decline in white matter integrity after systemic treatment for breast cancer: omitting skeletonization enhances sensitivity. Brain Imaging and Behavior, 2021, 15, 1191-1200.	1.1	18
5	Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. Molecular Psychiatry, 2021, 26, 5124-5139.	4.1	136
6	Brain structural abnormalities in obesity: relation to age, genetic risk, and common psychiatric disorders. Molecular Psychiatry, 2021, 26, 4839-4852.	4.1	76
7	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
8	Characterizing neuroanatomic heterogeneity in people with and without ADHD based on subcortical brain volumes. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1140-1149.	3.1	14
9	Analysis of structural brain asymmetries in attentionâ€deficit/hyperactivity disorder in 39 datasets. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1202-1219.	3.1	40
10	ENIGMAâ€Sleep: Challenges, opportunities, and the road map. Journal of Sleep Research, 2021, 30, e13347.	1.7	19
11	Do effects of methylphenidate on cognitive performance last beyond treatment? A randomized placebo-controlled trial in boys and men with ADHD. European Neuropsychopharmacology, 2021, 46, 1-13.	0.3	12
12	Imaging of the dopamine system with focus on pharmacological MRI and neuromelanin imaging. European Journal of Radiology, 2021, 140, 109752.	1.2	11
13	Animal studies in clinical MRI scanners: A custom setup for combined fMRI and deep-brain stimulation in awake rats. Journal of Neuroscience Methods, 2021, 360, 109240.	1.3	6
14	Brain Correlates of Suicide Attempt in 18,925 Participants Across 18 International Cohorts. Biological Psychiatry, 2021, 90, 243-252.	0.7	29
15	Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2021, 39, 3908-3917.	0.8	12
16	Postnatal Brain Growth Patterns in Pontocerebellar Hypoplasia. Neuropediatrics, 2021, 52, 163-169.	0.3	5
17	A Randomized Controlled Trial on the Effects of a 12-Week High- vs. Low-Intensity Exercise Intervention on Hippocampal Structure and Function in Healthy, Young Adults. Frontiers in Psychiatry, 2021, 12, 780095.	1.3	8
18	Anxiety, Mental Stress, and Sudden Cardiac Arrest: Epidemiology, Possible Mechanisms and Future Research. Frontiers in Psychiatry, 2021, 12, 813518.	1.3	9

#	Article	IF	Citations
19	Ultrahighâ€resolution MRI reveals structural brain differences in serotonin transporter knockout rats after sucrose and cocaine selfâ€administration. Addiction Biology, 2020, 25, e12722.	1.4	4
20	Subcortical surface morphometry in substance dependence: An ENIGMA addiction working group study. Addiction Biology, 2020, 25, e12830.	1.4	33
21	Psychoradiological Biomarkers for Psychopharmaceutical Effects. Neuroimaging Clinics of North America, 2020, 30, 53-63.	0.5	3
22	Methylphenidate Effects on Cortical Thickness in Children and Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. American Journal of Neuroradiology, 2020, 41, 758-765.	1.2	11
23	ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing. Translational Psychiatry, 2020, 10, 172.	2.4	121
24	ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies. NeuroImage, 2020, 219, 117031.	2.1	80
25	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. American Journal of Psychiatry, 2020, 177, 834-843.	4.0	120
26	Effects of 16 Weeks of Methylphenidate Treatment on Actigraph-Assessed Sleep Measures in Medication-Naive Children With ADHD. Frontiers in Psychiatry, 2020, 11, 82.	1.3	10
27	The influence of age-of-onset of antidepressant use on the acute CBF response to a citalopram challenge; a pharmacological MRI study. Psychiatry Research - Neuroimaging, 2020, 303, 111126.	0.9	2
28	White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. Radiology, 2019, 293, 186-192.	3.6	44
29	No Alterations of Brain Structural Asymmetry in Major Depressive Disorder: An ENIGMA Consortium Analysis. American Journal of Psychiatry, 2019, 176, 1039-1049.	4.0	39
30	Recurrent inference machines for reconstructing heterogeneous MRI data. Medical Image Analysis, 2019, 53, 64-78.	7.0	51
31	Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study. Psychiatry Research - Neuroimaging, 2019, 290, 5-13.	0.9	7
32	Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. American Journal of Psychiatry, 2019, 176, 531-542.	4.0	261
33	Dose-dependent effects of the selective serotonin reuptake inhibitor citalopram: A combined SPECT and phMRI study. Journal of Psychopharmacology, 2019, 33, 660-669.	2.0	6
34	Appetitive to aversive counterâ€conditioning as intervention to reduce reinstatement of rewardâ€seeking behavior: the role of the serotonin transporter. Addiction Biology, 2019, 24, 344-354.	1.4	2
35	The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a wellâ€defined cohort. Pediatric Blood and Cancer, 2018, 65, e26911.	0.8	21
36	<scp>d</scp>â€Cycloserine enhanced extinction of cocaineâ€induced conditioned place preference is attenuated in serotonin transporter knockout rats. Addiction Biology, 2018, 23, 120-129.	1.4	14

#	Article	IF	Citations
37	Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study. Brain Imaging and Behavior, 2018, 12, 324-334.	1.1	60
38	ADHD and maturation of brain white matter: A DTI study in medication naive children and adults. NeuroImage: Clinical, 2018, 17, 53-59.	1.4	40
39	Enhanced Amygdala-Striatal Functional Connectivity during the Processing of Cocaine Cues in Male Cocaine Users with a History of Childhood Trauma. Frontiers in Psychiatry, 2018, 9, 70.	1.3	15
40	Brain Hyperconnectivity >10 Years After Cisplatin-Based Chemotherapy for Testicular Cancer. Brain Connectivity, 2018, 8, 398-406.	0.8	11
41	S172. BRAIN METABOLITES AND THE RELATION WITH COGNITION AND PSYCHOTIC SYMPTOMS IN MEDICATION-FREE PSYCHOSIS AND CONTROLS: A PHARMACOLOGICAL MAGNETIC RESONANCE SPECTROSCOPY STUDY. Schizophrenia Bulletin, 2018, 44, S391-S392.	2.3	0
42	Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity. European Neuropsychopharmacology, 2018, 28, 1173-1179.	0.3	15
43	White matter alterations in cocaine users are negatively related to the number of additionally (ab)used substances. Addiction Biology, 2017, 22, 1048-1056.	1.4	35
44	QT prolongation by dexamphetamine: Does experience matter?. Journal of Cardiovascular Electrophysiology, 2017, 28, 912-916.	0.8	2
45	Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients. NeuroImage: Clinical, 2017, 15, 812-818.	1.4	25
46	Age-dependent effects of acute methylphenidate on amygdala reactivity in stimulant treatment-naive patients with Attention Deficit/Hyperactivity Disorder. Psychiatry Research - Neuroimaging, 2017, 269, 36-42.	0.9	16
47	The child's perspective on discomfort during medical research procedures: a descriptive study. BMJ Open, 2017, 7, e016077.	0.8	11
48	Mitochondrial Encephalopathy and Transient 3-Methylglutaconic Aciduria in ECHS1 Deficiency: Long-Term Follow-Up. JIMD Reports, 2017, 39, 83-87.	0.7	23
49	Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. Drug and Alcohol Dependence, 2017, 179, 117-123.	1.6	20
50	Timing of caloric intake during weight loss differentially affects striatal dopamine transporter and thalamic serotonin transporter binding. FASEB Journal, 2017, 31, 4345-4554.	0.2	23
51	A de novo missense mutation in the inositol 1,4,5â€triphosphate receptor type 1 gene causing severe pontine and cerebellar hypoplasia: Expanding the phenotype of ITPR1â€related spinocerebellar ataxia's. American Journal of Medical Genetics, Part A, 2017, 173, 207-212.	0.7	32
52	Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS ONE, 2017, 12, e0171724.	1.1	41
53	Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate. PLoS ONE, 2017, 12, e0172776.	1.1	7
54	Aversive Counterconditioning Attenuates Reward Signaling in the Ventral Striatum. Frontiers in Human Neuroscience, 2016, 10, 418.	1.0	7

#	Article	IF	Citations
55	White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. Aids, 2016, 30, 2329-2339.	1.0	67
56	Hyperresponsiveness of the Neural Fear Network During Fear Conditioning and Extinction Learning in Male Cocaine Users. American Journal of Psychiatry, 2016, 173, 1033-1042.	4.0	13
57	Cognitive Impairment in a Subset of Breast Cancer Patients After Systemic Therapyâ€"Results From a Longitudinal Study. Journal of Pain and Symptom Management, 2016, 52, 560-569.e1.	0.6	44
58	Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry, 2016, 73, 955.	6.0	56
59	The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology, 2016, 233, 3473-3501.	1.5	35
60	A power analysis for future clinical trials on the potential adverse effects of SSRIs on amygdala reactivity. Frontiers in Biology, 2016, 11, 256-259.	0.7	1
61	Frontostriatal anatomical connections predict age- and difficulty-related differences in reinforcement learning. Neurobiology of Aging, 2016, 46, 1-12.	1.5	8
62	Added value of fetal MRI in fetuses with suspected brain abnormalities on neurosonography: a systematic review and meta-analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 2949-2961.	0.7	42
63	Cognitive impairment and associated loss in brain white microstructure in aircrew members exposed to engine oil fumes. Brain Imaging and Behavior, 2016, 10, 437-444.	1.1	19
64	Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls. Brain Imaging and Behavior, 2016, 10, 548-558.	1.1	30
65	Dysfunctional amygdala activation and connectivity with the prefrontal cortex in current cocaine users. Human Brain Mapping, 2015, 36, 4222-4230.	1.9	22
66	Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Human Brain Mapping, 2015, 36, 4638-4647.	1.9	53
67	Strokelike Episodes and Cutis Marmorata Telangiectatica Congenita. Journal of Child Neurology, 2015, 30, 129-132.	0.7	3
68	Effects of methylphenidate during emotional processing in amphetamine users: preliminary findings. Brain Imaging and Behavior, 2015, 9, 878-886.	1.1	8
69	Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. Neuroscience, 2015, 309, 243-258.	1.1	23
70	Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment â€" The role of fatigue. NeuroImage: Clinical, 2015, 7, 547-554.	1.4	104
71	Very Late Treatment-Related Alterations in Brain Function of Breast Cancer Survivors. Journal of the International Neuropsychological Society, 2015, 21, 50-61.	1.2	29
72	Dopaminergic System Dysfunction in Recreational Dexamphetamine Users. Neuropsychopharmacology, 2015, 40, 1172-1180.	2.8	25

#	Article	IF	Citations
73	Neurotoxicity in breast cancer survivors â‰¥10Âyears post-treatment is dependent on treatment type. Brain Imaging and Behavior, 2015, 9, 275-284.	1.1	69
74	Increased Response to a 5-HT Challenge After Discontinuation of Chronic Serotonin Uptake Inhibition in the Adult and Adolescent Rat Brain. PLoS ONE, 2014, 9, e99873.	1.1	9
75	Reduced Frontal Brain Volume in Non-Treatment-Seeking Cocaine-Dependent Individuals: Exploring the Role of Impulsivity, Depression, and Smoking. Frontiers in Human Neuroscience, 2014, 8, 7.	1.0	36
76	Effects of Chronic Fluoxetine Treatment on Neurogenesis and Tryptophan Hydroxylase Expression in Adolescent and Adult Rats. PLoS ONE, 2014, 9, e97603.	1.1	51
77	Correlation Between Clinical and Histologic Findings in the Human Neonatal Hippocampus After Perinatal Asphyxia. Journal of Neuropathology and Experimental Neurology, 2014, 73, 324-334.	0.9	33
78	Long-Term Oral Methylphenidate Treatment in Adolescent and Adult Rats: Differential Effects on Brain Morphology and Function. Neuropsychopharmacology, 2014, 39, 263-273.	2.8	32
79	The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. BMC Psychiatry, 2014, 14, 48.	1.1	30
80	Relationship between trait impulsivity and cortical volume, thickness and surface area in male cocaine users and non-drug using controls. Drug and Alcohol Dependence, 2014, 144, 210-217.	1.6	33
81	Increase in central striatal dopamine transporters in patients with Shwachmanâ€“Diamond syndrome: Additional evidence of a brain phenotype. American Journal of Medical Genetics, Part A, 2013, 161, 102-107.	0.7	9
82	Neurologic Abnormalities in HIV-1 Infected Children in the Era of Combination Antiretroviral Therapy. PLoS ONE, 2013, 8, e64398.	1.1	31
83	Preliminary evidence of hippocampal damage in chronic users of ecstasy. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 83-85.	0.9	21
84	Incidental Head and Neck Findings on MRI in Young Healthy Volunteers: Prevalence and Clinical Implications. American Journal of Neuroradiology, 2012, 33, 1971-1974.	1.2	28
85	The Effects of Ecstasy (MDMA) on Brain Serotonin Transporters Are Dependent on Age-of-First Exposure in Recreational Users and Animals. PLoS ONE, 2012, 7, e47524.	1.1	18
86	The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System. Journal of Visualized Experiments, 2012, , .	0.2	7
87	Late effects of highâ€dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Human Brain Mapping, 2012, 33, 2971-2983.	1.9	218
88	Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment. Psychopharmacology, 2012, 221, 329-339.	1.5	30
89	How the aging brain translates motivational incentive into action: The role of individual differences in striato-cortical white matter pathways. Developmental Cognitive Neuroscience, 2011, 1, 530-539.	1.9	8
90	Fluoxetine Exerts Age-Dependent Effects on Behavior and Amygdala Neuroplasticity in the Rat. PLoS ONE, 2011, 6, e16646.	1.1	72

#	Article	IF	Citations
91	Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping, 2011, 32, 1206-1219.	1.9	243
92	White Matter Fractional Anisotropy Correlates With Speed of Processing and Motor Speed in Young Childhood Cancer Survivors. International Journal of Radiation Oncology Biology Physics, 2009, 74, 837-843.	0.4	146
93	Cerebral impairment in chronic solventâ€induced encephalopathy. Annals of Neurology, 2008, 63, 572-580.	2.8	44
94	Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain, 2008, 131, 2936-2945.	3.7	85
95	Neurotoxic effects of ecstasy on the thalamus. British Journal of Psychiatry, 2008, 193, 289-296.	1.7	33
96	A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users. Neuropsychopharmacology, 2007, 32, 458-470.	2.8	59
97	Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. Journal of Psychopharmacology, 2006, 20, 389-399.	2.0	58
98	Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. Journal of Psychopharmacology, 2006, 20, 164-175.	2.0	76
99	Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. Journal of Psychopharmacology, 2006, 20, 226-235.	2.0	48
100	Validation of [123I]Î²-CIT SPECT to Assess Serotonin Transporters In Vivo in Humans: a Double-Blind, Placebo-Controlled, Crossover Study with the Selective Serotonin Reuptake Inhibitor Citalopram. Neuropsychopharmacology, 2005, 30, 996-1005.	2.8	64
101	The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. International Journal of Methods in Psychiatric Research, 2005, 14, 167-185.	1.1	45
102	Mood disorders and serotonin transporter density in ecstasy usersâ€"the influence of long-term abstention, dose, and gender. Psychopharmacology, 2004, 173, 376-382.	1.5	71
103	Validity of in vivo [I]?-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. European Neuropsychopharmacology, 2004, 14, 185-189.	0.3	16
104	Designer drugs: how dangerous are they?. , 2003, , 61-83.		9
105	Ecstasy in the Brain. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 125-129.	0.9	11
106	The Acute and Chronic Effects of MDMA (â€œEcstasyâ€) on Cortical 5-HT2A Receptors in Rat and Human Brain. Neuropsychopharmacology, 2002, 26, 387-396.	2.8	128
107	Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]Î²-CIT SPECT study â€“ preliminary report. Psychopharmacology, 2002, 159, 335-340.	1.5	71
108	Validity of [123I]?-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse, 2002, 46, 199-205.	0.6	31

#	Article	IF	Citations
109	Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results. American Journal of Neuroradiology, 2002, 23, 231-7.	1.2	46
110	Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophrenia Research, 2001, 47, 59-67.	1.1	79
111	Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biological Psychiatry, 2001, 50, 550-554.	0.7	59
112	Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet, The, 2001, 358, 1864-1869.	6.3	210
113	Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy"). Archives of General Psychiatry, 2001, 58, 901.	13.8	176
114	Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology, 2001, 155, 107-109.	1.5	13
115	Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Human Psychopharmacology, 2001, 16, 579-588.	0.7	43
116	Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus. Synapse, 2001, 39, 193-200.	0.6	17
117	Effects of Ecstasy (MDMA) on the Brain in Abstinent Users: Initial Observations with Diffusion and Perfusion MR Imaging. Radiology, 2001, 220, 611-617.	3.6	53
118	Memory disturbances in â€Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology, 2000, 148, 322-324.	1.5	189
119	Effect of age and gender on dopamine transporter imaging with [123 I]FP-CIT SPET in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 867-869.	3.3	253
120	[123 I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 346-349.	3.3	31
121	Comparative in vivo study of iodine-123-labeled ?-cit and nor-?-cit binding to serotonin transporters in rat brain. Synapse, 1999, 34, 77-80.	0.6	11
122	Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Research - Neuroimaging, 1999, 92, 33-44.	0.9	42
123	Iodine-123 labelled nor-Î²-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1666-1669.	3.3	16